New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
07:36 EDTFOLDAmicus Theraputics announces positive results from Phase 2 Chaperone-ERT study
Amicus Therapeutics announced positive preliminary results from all 4 dose cohorts in a Phase 2 study to evaluate the safety and pharmacokinetic, or PK, effects of the pharmacological chaperone AT2220 co-administered with enzyme replacement therapy, or ERT, for Pompe disease, Myozyme and Lumizyme. Myozyme and Lumizyme are the first and only approved treatments for Pompe disease. Based on the Study 010 results, Amicus expects to initiate a repeat-dose clinical study in Q3.
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
10:06 EDTFOLDOptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD GME YOKU SPLS DKS WUBA ARWR ACHN
August 21, 2014
10:22 EDTFOLDOptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD VHC ACHN JCP WB JD YPF
August 20, 2014
11:42 EDTFOLDOptions with decreasing implied volatility
Subscribe for More Information
11:09 EDTFOLDHigh option volume stocks
Subscribe for More Information
10:31 EDTFOLDAmicus price target raised its price target to $14 from $9 at Cowen
Subscribe for More Information
09:36 EDTFOLDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FOLD TSLA TWTR WHX FB TM NFLX X EOG
09:07 EDTFOLDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PetSmart (PETM), up 2,1%... Staples (SPLS), up 2%... E-House (EJ), up 2.5%. HIGHER: Fairchild (FCS), up 4% after Bloomberg says Infineon (IFNNY) is near a deal to buy a U.S. semiconductor company for $2B... Amicus Therapeutics (FOLD), up 18.4% after reporting positive Phase 3 data from the Fabry study. DOWN AFTER EARNINGS: Lowe's (LOW), down 3%... Tarena (TEDU), down 9%... Leju (LEJU), down 4.2%... JA Solar (JASO), down 5%. LOWER: Hertz (HTZ), down 12.7% after downgraded at JPMorgan and Deutsche Bank following the company's decision to withdraw its FY14 guidance... NovaBay (NBY), down 35.2% after primary, secondary endpoints were not met in its NVC-422 study... RGS Energy (RGSE), down 14.9% after downgraded at Roth Capital following Q2 earnings results.
06:34 EDTFOLDAmicus Therapeutics to host conference call
Conference call to discuss results of Phase 3 Fabry monotherapy study will be held on August 20 at 8 am. Webcast Link
06:08 EDTFOLDAmicus Therapeutics reports positive Phase 3 data from Fabry study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use